GFORCE-PD still going strong in 2016
(2017) In npj Parkinson's Disease 3.- Abstract
- In 2014, a new initiative was undertaken by groups working on plans for the transplantation of stem-cell-based derived dopaminergic neurons for treating Parkinson’s disease patients. This GForce-PD group held its annual meeting on 18–19 April 2016 in Chicago at Rush University to discuss their progress and the challenges that the translation of this experimental therapy still faces. Over 2 days, the key issues were discussed around the cell lines that will be used, the differentiation protocols, preclinical testing, GMP-adaptation, and cell manufacturing to allow first in human clinical trials, which are anticipated to start in 2017–2018. GForce-PD members also discussed how they can improve outreach and be of better service to the... (More)
- In 2014, a new initiative was undertaken by groups working on plans for the transplantation of stem-cell-based derived dopaminergic neurons for treating Parkinson’s disease patients. This GForce-PD group held its annual meeting on 18–19 April 2016 in Chicago at Rush University to discuss their progress and the challenges that the translation of this experimental therapy still faces. Over 2 days, the key issues were discussed around the cell lines that will be used, the differentiation protocols, preclinical testing, GMP-adaptation, and cell manufacturing to allow first in human clinical trials, which are anticipated to start in 2017–2018. GForce-PD members also discussed how they can improve outreach and be of better service to the Parkinson's disease (PD) community and help them to make the best possible decisions when pursuing stem cell treatments. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/26a9bb38-82c4-4e20-93ef-f09a4e032e05
- author
- Parmar, Malin LU ; Takahashi, Jun ; Studer, Lorenz and Barker, Roger A LU
- organization
- publishing date
- 2017-02-23
- type
- Contribution to journal
- publication status
- published
- subject
- in
- npj Parkinson's Disease
- volume
- 3
- article number
- 16014
- publisher
- Springer Nature
- external identifiers
-
- scopus:85060614515
- ISSN
- 2373-8057
- DOI
- 10.1038/npjparkd.2016.14
- language
- English
- LU publication?
- yes
- id
- 26a9bb38-82c4-4e20-93ef-f09a4e032e05
- date added to LUP
- 2019-09-20 11:41:55
- date last changed
- 2022-02-16 00:09:38
@article{26a9bb38-82c4-4e20-93ef-f09a4e032e05, abstract = {{In 2014, a new initiative was undertaken by groups working on plans for the transplantation of stem-cell-based derived dopaminergic neurons for treating Parkinson’s disease patients. This GForce-PD group held its annual meeting on 18–19 April 2016 in Chicago at Rush University to discuss their progress and the challenges that the translation of this experimental therapy still faces. Over 2 days, the key issues were discussed around the cell lines that will be used, the differentiation protocols, preclinical testing, GMP-adaptation, and cell manufacturing to allow first in human clinical trials, which are anticipated to start in 2017–2018. GForce-PD members also discussed how they can improve outreach and be of better service to the Parkinson's disease (PD) community and help them to make the best possible decisions when pursuing stem cell treatments.}}, author = {{Parmar, Malin and Takahashi, Jun and Studer, Lorenz and Barker, Roger A}}, issn = {{2373-8057}}, language = {{eng}}, month = {{02}}, publisher = {{Springer Nature}}, series = {{npj Parkinson's Disease}}, title = {{GFORCE-PD still going strong in 2016}}, url = {{http://dx.doi.org/10.1038/npjparkd.2016.14}}, doi = {{10.1038/npjparkd.2016.14}}, volume = {{3}}, year = {{2017}}, }